

EXHIBIT A

PENDING CLAIMS UPON ENTRY OF THE INSTANT AMENDMENT (FILED SEPTEMBER 24, 2001)

**APPLICATION SERIAL NO.: 09/610,118
ATTORNEY DOCKET NO.: 7853-211**

132. A substantially purified antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

133. The antibody of claim 132, wherein the antibody comprises a variable heavy (VH) CDR having an amino acid sequence of a VH CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

134. The antibody of claim 132, wherein the antibody comprises a variable light (VL) CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

135. The antibody of claim 133, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

136. The antibody of claim 134 or 135, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

137. The antibody of claim 136, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

138. The antibody of claim 133, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

139. The antibody of claim 138, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:61.

140. The antibody of claim 138 or 139, further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

141. The antibody of claim 140, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

142. The antibody of claim 133, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

143. The antibody of claim 142, wherein the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62.

144. The antibody of claim 143, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

145. The antibody of claim 144, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

146. The antibody of claim 133, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

147. The antibody of claim 146, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO:63.

148. The antibody of claim 147, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

149. The antibody of claim 148, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

150. The antibody of claim 134, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

151. The antibody of claim 150, wherein the VL CDR1 comprises the amino acid sequence of SEQ ID NO:64.

152. The antibody of claim 150 or 151, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

153. The antibody of claim 152, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

154. The antibody of claim 150, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

155. The antibody of claim 154, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

156. The antibody of claim 155, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

157. The antibody of claim 134, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

158. The antibody of claim 157, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO:65.

159. The antibody of claim 157 or 158, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

160. The antibody of claim 159, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

161. The antibody of claim 138 further comprising a VH CDR2 domain having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

162. The antibody of claim 138 further comprising a VH CDR3 domain having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

163. The antibody of claim 138 further comprising:
- (a) a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
 - (b) a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

164. The antibody of claim 138 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

165. The antibody of claim 138 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

166. The antibody of claim 135 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

167. The antibody of claim 166, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

168. The antibody of claim 138 further comprising:
(a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
(b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

169. The antibody of claim 138 further comprising:
(a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
(b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

170. The antibody of claim 169, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

171. The antibody of claim 138 further comprising:
- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
 - (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

172. The antibody of claim 171, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

173. The antibody of claim 138 further comprising:
- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
 - (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
 - (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

174. The antibody of claim 173, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

175. The antibody of claim 142 further comprising a VH CDR3 having the amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

176. The antibody of claim 142 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

177. The antibody of claim 142 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

178. The antibody of claim 142 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

179. The antibody of claim 178, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

180. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

181. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

182. The antibody of claim 181, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

183. The antibody of claim 142 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

184. The antibody of claim 183, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

185. The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

186. The antibody of claim 185, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

187. The antibody of claim 146 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

188. The antibody of claim 146 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

189. The antibody of claim 146 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

190. The antibody of claim 189, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

191. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

192. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

193. The antibody of claim 192, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

194. The antibody of claim 146 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

195. The antibody of claim 194, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

196. The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

197. The antibody of claim 196, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

198. The antibody of claim 161, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

199. The antibody of claim 198, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

200. The antibody of claim 198, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

201. The antibody of claim 198, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

202. The antibody of claim 201, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

203. The antibody of claim 199 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

204. The antibody of claim 203, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

205. The antibody of claim 200 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

206. The antibody of claim 205, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

207. The antibody of claim 199, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

208. The antibody of claim 207, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

209. The antibody of claim 208, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

210. The antibody of claim 162, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

211. The antibody of claim 210, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

212. The antibody of claim 210, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

213. The antibody of claim 210, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

214. The antibody of claim 213, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

215. The antibody of claim 211, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

216. The antibody of claim 212, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

217. The antibody of claim 216, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

218. The antibody of claim 211 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

219. The antibody of claim 218, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

220. The antibody of claim 218 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

221. The antibody of claim 220, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

222. The antibody of claim 163 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

223. The antibody of claim 163 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

224. The antibody of claim 163 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

225. The antibody of claim 224, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

226. The antibody of claim 163 further comprising:
(a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
(b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

227. The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

228. The antibody of claim 227, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

229. The antibody of claim 163 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

230. The antibody of claim 229, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

231. The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

232. The antibody of claim 231, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

233. The antibody of claim 175 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

234. The antibody of claim 175 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

235. The antibody of claim 175 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

236. The antibody of claim 235, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

237. The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

238. The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

239. The antibody of claim 238, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

240. The antibody of claim 175 further comprising:
- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
 - (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

241. The antibody of claim 240, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

242. The antibody of claim 175 further comprising:
- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
 - (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
 - (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

243. The antibody of claim 242, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

244. The antibody of claim 132 wherein the CDR comprises the amino acid sequence of SEQ ID NO:66.

245. The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

246. The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

247. The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

248. The antibody of claim 245 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

249. The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

250. The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

251. The antibody of claim 248 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

252. A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

253. The antibody of claim 252 wherein the antibody comprises the amino acid sequence of SEQ ID NO:66.

254. A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442 for binding to a TANGO 268 antigen.

255. The antibody of claim 254 wherein the antibody comprises the amino acid sequence of SEQ ID NO:66.

256. The antibody of claim 137, wherein the antibody is a monoclonal antibody.
257. The antibody of claim 137, wherein the antibody is a human antibody.
258. The antibody of claim 137, wherein the antibody is a humanized antibody.
259. The antibody of claim 137, wherein the antibody is a Fab fragment.
260. The antibody of claim 137, wherein the antibody is an scFv.
261. The antibody of claim 137, wherein the antibody is conjugated to a therapeutic or drug moiety.
262. The antibody of claim 137, wherein the antibody is conjugated to a detectable substance.
263. A pharmaceutical composition comprising the antibody of claim 137 and a pharmaceutically acceptable carrier.
264. A kit comprising the antibody of claim 137 and instructions for use, in one or more containers.